The agency said the pathway aims to improve access to breakthrough medical devices. The MDMA said it is disappointed by the ruling.
“We appreciate CMS’ efforts to improve the Coverage with Evidence Development pathway, but limiting eligibility to only five technologies a year means it is unlikely to meaningfully improve access or address disincentives to medical innovation caused by the current Medicare coverage process,” the organization said in a statement.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
